Table 3.
Clinical outcomes of patients with Acinetobacter calcoaceticus-Acinetobacter baumannii complex bacteremia stratified by presence of multidrug resistance in A. baumannii isolates.
| Outcomea | Susceptible A. baumannii (n = 24) | MDR A. baumannii (n = 92) | Non-baumannii ACB complex (n = 31) | p-value | ||
|---|---|---|---|---|---|---|
| Overall | Susceptible A. baumannii vs. MDR A. baumannii | Susceptible A. baumannii vs. non-baumannii ACB complex | ||||
| Days to negative cultures, median (range)b | 2 (1–5) | 1 (1–7) | 2 (1–6) | 0.49 | ||
| Received appropriate therapy | 24 (100) | 63 (69) | 29 (94) | < 0.01 | < 0.01 | 0.50 |
| Days to appropriate therapy, median (range)c | 0.5 (0–6) | 2 (0–13) | 1 (0–4) | < 0.01 | < 0.01 | 0.93 |
| Hospital LOS postculture, median days (range) | 6 (2–38) | 11.5 (2–69) | 5 (0–28) | 0.01 | 0.09 | 0.12 |
| 30-day mortality | 2 (8) | 40 (44) | 4 (13) | < 0.01 | < 0.01 | 0.69 |
| 14-day mortality | 2 (8) | 33 (36) | 4 (13) | < 0.01 | 0.01 | 0.69 |
| Days to mortality, median (range) | 10.5 (6–15) | 2.5 (0–27) | 1.5 (1–5) | 0.40 | ||
Data are No. (%) unless otherwise specified
ACB, Acinetobacter calcoaceticus-Acinetobacter baumannii complex; MDR, multidrug resistant; LOS, length of stay
a
Statistical tests were also performed comparing outcomes between susceptible A. baumannii and susceptible non-baumannii ACB complex and also between MDR A. baumannii and MDR non-baumannii ACB complex. No significant differences were found (data not shown).
b
For 110 patients with repeat blood cultures.
c
For 117 patients receiving appropriate therapy